3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
2
Withdrawn
1
Terminated
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
24
Triple Negative Breast Neoplasms
11
Breast Neoplasms
11
Carcinoma, Transitional Cell
9
Small Cell Lung Carcinoma
7
Carcinoma, Renal Cell
7
Carcinoma, Hepatocellular
7
Neoplasm Metastasis
6
Melanoma
6
Colorectal Neoplasms
6
Lung Neoplasms
5
Recurrence
4
Neoplasms
4
Urinary Bladder Neoplasms
3
Lymphoma, B-Cell
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Solid Tumors
2
Solid Tumor
2
Pancreatic Neoplasms
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Liver Neoplasms
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Merkel Cell
2
Brain Neoplasms
2
Advanced Solid Tumor
2
Urologic Neoplasms
1
Interventions
Fluorouracil
25
Oxaliplatin
24
Irinotecan
24
Leucovorin
23
Bevacizumab
23
Capecitabine
18
Cetuximab
15
Radiotherapy
6
Gene Expression Profiling
5
regorafenib
4
Immunohistochemistry
4
Gemcitabine
4
Folfox protocol
4
Colonoscopy
4
Cisplatin
4
Celecoxib
4
Amplified Fragment Length Polymorphism Analysis
4
Reverse Transcriptase Polymerase Chain Reaction
3
Receptor Protein-Tyrosine Kinases
3
Polymerase Chain Reaction
3
Nivolumab
3
Mitomycin
3
Doxorubicin
3
Cyclophosphamide
3
Cholecalciferol
3
Biopsy
3
Aspirin
3
sargramostim
2
pembrolizumab
2
ixabepilone
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Colonic Neoplasms
×
atezolizumab
×
Clear all
NCT04108481
2025-03-28
iRE-C
University of Iowa
Phase 1
Terminated
5 enrolled